| Literature DB >> 26415560 |
Kazuaki Kameda1, Shun-Ichi Kimura1, Yu Akahoshi1, Hirofumi Nakano1, Naonori Harada1, Tomotaka Ugai1, Hidenori Wada1, Ryoko Yamasaki1, Yuko Ishihara1, Koji Kawamura1, Kana Sakamoto1, Masahiro Ashizawa1, Miki Sato1, Kiriko Terasako-Saito1, Hideki Nakasone1, Misato Kikuchi1, Rie Yamazaki1, Junya Kanda1, Shinichi Kako1, Aki Tanihara1, Junji Nishida1, Yoshinobu Kanda2.
Abstract
Bloodstream infections (BSI) are still important complications after allogeneic hematopoietic stem cell transplantation (allo-SCT). Patients who are receiving corticosteroid therapy can develop BSI without fever. The utility of surveillance blood cultures in these situations is controversial. We retrospectively analyzed 74 patients who received a corticosteroid consisting of ≥.5 mg/kg prednisolone or equivalent after allo-SCT. In principle, we performed surveillance blood culture weekly for these patients. Sixteen patients (21.6%) developed definite BSI. In a multivariate analysis, a myeloablative conditioning regimen, high-risk disease status at allo-SCT, and the presence of a central venous catheter at the initiation of corticosteroid therapy were identified as independent significant risk factors for the development of definite BSI. At the first definite BSI episode, 7 patients (46.7%) were afebrile and diagnosed by surveillance blood culture. However, 6 of these 7 afebrile patients showed various signs that could be attributed to infection at the time of positive blood culture. In conclusion, patients receiving corticosteroid therapy after allo-SCT frequently develop afebrile BSI. Although surveillance blood culture might be beneficial in these situations, it also seems important to not miss the signs of BSI, even when patients are afebrile.Entities:
Keywords: Allogeneic hematopoietic stem cell transplantation; Bloodstream infection; Corticosteroid; Surveillance blood culture
Mesh:
Substances:
Year: 2015 PMID: 26415560 DOI: 10.1016/j.bbmt.2015.09.019
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742